|
Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie/Stemcentrx; Ipsen; Lexicon; Novartis; Voluntis |
Research Funding - eFFECTOR Therapeutics; Eisai; Guardant Health; Hutchison MediPharma; Merck; Novartis |
|
|
Stock and Other Ownership Interests - MolecularMatch; Navire |
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; Holy Stone Healthcare; Ipsen; Karyopharm Therapeutics; Lilly; Merck; Natera; Navire; Novartis; Pierre Fabre; Redx Pharma; Roche; Symphogen |
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Adlai Nortye |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Medicaroid; MORE Health |
Research Funding - Agendia |